Heart & Lung

AtlantiCare First in Northeast to Deploy Optellum AI Alongside Robotics for Early Lung Cancer Diagnosis and Treatment

Retrieved on: 
星期四, 二月 23, 2023

EGG HARBOR TOWNSHIP, N.J., Feb. 23, 2023 /PRNewswire/ -- AtlantiCare is the first healthcare system in the northeastern U.S. to use Optellum's Virtual Nodule Clinic. Located in New Jersey, it is integrating the innovative technology into its early lung cancer diagnosis program at its Heart & Lung and Cancer Care institutes at AtlantiCare Regional Medical Center (ARMC).

Key Points: 
  • Located in New Jersey, it is integrating the innovative technology into its early lung cancer diagnosis program at its Heart & Lung and Cancer Care institutes at AtlantiCare Regional Medical Center (ARMC).
  • Lung cancer is among the most common types of cancer and the leading cause of cancer deaths in the world, according to the American Lung Association .
  • Optellum's integrated Lung Cancer Prediction capability also helps AtlantiCare clinicians prioritize patients at high risk of having lung cancer.
  • "We have already identified suspicious tumors in individuals who have no known risk of lung cancer through this technology," added Borah.

scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting

Retrieved on: 
星期二, 六月 7, 2022

We are very pleased to present the primary results from the FREEDOM-HF study as an encore oral presentation at this years AAHFN annual meeting.

Key Points: 
  • We are very pleased to present the primary results from the FREEDOM-HF study as an encore oral presentation at this years AAHFN annual meeting.
  • Abstracts and moderated abstracts presented at the meeting will be published in Heart and Lung: The Journal of Acute and Critical Care, the official journal of the AAHFN.
  • If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.
  • The Companys lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease.